U.S. markets open in 50 minutes
  • S&P Futures

    3,937.00
    +37.50 (+0.96%)
     
  • Dow Futures

    31,542.00
    +329.00 (+1.05%)
     
  • Nasdaq Futures

    11,918.25
    +77.50 (+0.65%)
     
  • Russell 2000 Futures

    1,792.60
    +20.40 (+1.15%)
     
  • Crude Oil

    111.30
    +1.02 (+0.92%)
     
  • Gold

    1,858.80
    +16.70 (+0.91%)
     
  • Silver

    22.09
    +0.42 (+1.94%)
     
  • EUR/USD

    1.0660
    +0.0098 (+0.93%)
     
  • 10-Yr Bond

    2.8440
    +0.0570 (+2.05%)
     
  • Vix

    29.16
    -0.19 (-0.65%)
     
  • GBP/USD

    1.2571
    +0.0075 (+0.60%)
     
  • USD/JPY

    127.6470
    -0.2030 (-0.16%)
     
  • BTC-USD

    30,414.83
    +299.57 (+0.99%)
     
  • CMC Crypto 200

    682.56
    +9.18 (+1.36%)
     
  • FTSE 100

    7,475.00
    +85.02 (+1.15%)
     
  • Nikkei 225

    27,001.52
    +262.49 (+0.98%)
     

Why Editas Medicine's Shares Fell 28.9% This Week

·3 min read
Why Editas Medicine's Shares Fell 28.9% This Week
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Editas Medicine (NASDAQ: EDIT), a genome editing biotech company that uses CRISPR/Cas9 and CRISPR/Cas12a genome editing systems to develop therapies, saw its shares plummet 28.9% this week, according to data from S&P Global Market Intelligence. Editas' shares have steadily fallen this year, but it is hardly alone among gene-editing companies. Intellia Therapeutics is down more than 63% so far this year while CRISPR Therapeutics has seen its shares drop more than 38%.